TI
CRVS icon

Trexquant Investment’s Corvus Pharmaceuticals CRVS Stock Holding History

Trexquant Investment’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,226
Closed -$90.1K – 1634
2025
Q3 		$90.1K Buy
+12,226
New +$62.6K ﹤0.01% 1538
2018
Q4 		– Sell
-12,483
Closed -$107K – 1070
2018
Q3 		$107K Buy
+12,483
New +$125K 0.01% 892
2018
Q1 		– Sell
-17,971
Closed -$186K – 1120
2017
Q4 		$186K Buy
+17,971
New +$230K 0.02% 954

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trexquant Investment's CRVS Position: Q4 2025 in Review

Trexquant Investment sold out of Corvus Pharmaceuticals (CRVS) in Q4 2025, closing a stake of 12,226 shares — an estimated $90.1K sold.

Trexquant Investment first reported a position in CRVS in Q4 2017 and held it in 3 quarters. The position peaked at $186K in Q4 2017. 124 funds tracked by Wall St. Rank hold CRVS as of Q4 2025.

  • Trexquant Investment reported no remaining Corvus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Trexquant Investment sold 12,226 Corvus Pharmaceuticals shares in Q4 2025, an estimated $90.1K.
  • Trexquant Investment first reported a position in Corvus Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Trexquant Investment's Corvus Pharmaceuticals position peaked at $186K in Q4 2017.
  • 124 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2025.

Based on Trexquant Investment's 13F filing for Q4 2025, filed 17 Feb 2026.